Malta - English - Medicines Authority

venus pharma gmbh am bahnhof 1-3, werne, d 59368, germany - powder for solution for infusion or injection - cefuroxime 750 mg - antibacterials for systemic use

Malta - English - Medicines Authority

venus pharma gmbh am bahnhof 1-3, werne, d 59368, germany - powder for solution for infusion or injection - cefuroxime 1500 mg - antibacterials for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - ramipril - tablet - 1.25 milligram(s) - ace inhibitors, plain; ramipril

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - ramipril - tablet - 2.5 milligram(s) - ace inhibitors, plain; ramipril

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - ramipril - tablet - 10 milligram(s) - ace inhibitors, plain; ramipril

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - ramipril - tablet - 5 milligram(s) - ace inhibitors, plain; ramipril

Canada - English - Health Canada

total health centre - gnaphalium leontopodium - liquid - 1x - gnaphalium leontopodium 1x - homeopathic products

European Union - English - EMA (European Medicines Agency)

biopartners gmbh - somatropin - turner syndrome; dwarfism, pituitary - pituitary and hypothalamic hormones and analogues - paediatric poulationlong-term treatment of children (2 to 11 years old) and adolescents (12 to 18 years old) with growth failure due to an inadequate secretion of normal endogenous growth hormone.treatment of short stature in children with turner syndrome, confirmed by chromosome analysis.treatment of growth retardation in pre-pubertal children with chronic renal insufficiency.adult patientsreplacement therapy in adults with pronounced growth hormone deficiency of either childhood- or adult-onset aetiology.patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic-pituitary pathology and at least one additional known deficiency of a pituitary hormone not being prolactin. these patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. in patients with childhood-onset isolated growth hormone deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like growth factor-1 (igf-1) concentrations (< 2 standard deviation score (sds)), who may be considered for one test. the cut-off point of the dynamic test should be strict.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 45578 - mitral/tricuspid annuloplasty ring - the contour 3d? annuloplasty ring, model 690r, consists of a titanium core encapsulated within silicone and covered with polyester fabric. the contour 3d? ring is designed for implantation in the tricuspid position, and is shaped to closely approximate the healthy tricuspid annular three dimensional contours. the contour 3d? ring is marked at three points by coloured sutures. the three markers correspond to the commissures of the tricuspid valve. the contour 3d ring is indicated for the reconstruction and/or remodeling of pathological tricuspid valves.

European Union - English - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ritonavir - hiv infections - antivirals for systemic use, - ritonavir is indicated in combination with other antiretroviral agents for the treatment of hiv-1-infected patients (adults and children of two years of age and older).,